Skip to main content
Erschienen in: Reactions Weekly 1/2016

01.03.2016 | Case report

Adalimumab

Tuberculosis reactivation: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Zatyka E, et al. Utility of a screening protocol incorporating an interferon-gamma release assay (IGRA) on detection and decision to treat latent tuberculosis infection (LTBI) prior to anti-TNF therapy. Thorax 70 (Suppl. 3): A206-A207 abstr. P255, 2015 [abstract] - United Kingdom Zatyka E, et al. Utility of a screening protocol incorporating an interferon-gamma release assay (IGRA) on detection and decision to treat latent tuberculosis infection (LTBI) prior to anti-TNF therapy. Thorax 70 (Suppl. 3): A206-A207 abstr. P255, 2015 [abstract] - United Kingdom
Metadaten
Titel
Adalimumab
Tuberculosis reactivation: 2 case reports
Publikationsdatum
01.03.2016
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2016
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-016-15445-y

Weitere Artikel der Ausgabe 1/2016

Reactions Weekly 1/2016 Zur Ausgabe

Case report

Epinephrine

Case report

Carvedilol

Case report

Ceftriaxone